Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

5(71.4%)

N/A

1(14.3%)

Phase 2

1(14.3%)

7Total

Phase 1(5)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07364669Phase 1Completed

Pharmacokinetic and Pharmacodynamic Effects of Insulex® R in Comparison to Humulin® R in Healthy Subjects

Role: collaborator

NCT04004325Phase 1Terminated

A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis

Role: collaborator

NCT06036784Phase 1Completed

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects

Role: collaborator

NCT04048135Phase 1Completed

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

Role: collaborator

NCT04956263Phase 2Completed

A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes

Role: collaborator

NCT04502212Not ApplicableCompleted

Pilot Study to Assess the Effects of Hepatic Ultrasound Insonification on Subjects With T2DM

Role: collaborator

NCT03261739Phase 1Completed

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

Role: collaborator

All 7 trials loaded